慢性難治性咳嗽市場：薬剤タイプ別、流通チャネル別-2025-2030年の世界予測

慢性難治性咳嗽市場は、2023年に55億7,000万米ドルと評価され、2024年には58億8,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には83億2,000万米ドルになると予測されています。

慢性難治性咳嗽（CRC）とは、標準治療に反応しない持続性の咳であり、しばしば生活の質に影響を与えます。CRCの範囲と定義は、治療的介入や基礎疾患の管理に抵抗性を示す8週間以上続く咳という特徴に焦点を当てています。効果的なCRC治療の必要性は、未治療の症状に伴う患者の多大な不快感とヘルスケアコストから生じる。最終用途の範囲には、神経経路、咳反射調節、サイトカイン受容体拮抗を標的とする潜在的治療が含まれ、製薬会社、研究機関、医療提供者などが主要利害関係者となります。

CRC市場の主な成長要因としては、ヘルスケア専門家のCRCに対する認識の高まり、診断技術の進歩、新規治療アプローチのための調査投資の増加などが挙げられます。咳関連疾患の素因を持つ人口の高齢化は、市場拡大にさらに影響を与えます。最新の治療機会は個別化医療にあり、遺伝子や表現型のプロファイリングに基づくオーダーメイド治療が治療効果を高める可能性があります。AI主導の診断ツールや遠隔医療プラットフォームへの投資も大きな可能性を秘めており、遠隔地からの効果的なCRC管理が可能になります。

とはいえ、CRCの病態生理の理解が限られていること、研究開発コストが高いこと、規制要件が厳しいことなどの課題によって、市場の成長は制約されています。咳の誘因が不均一であることが臨床試験を複雑にしており、しばしば大規模で長期にわたる研究が必要となります。特に新興諸国では、患者のヘルスケア施設へのアクセスが限られていることが、市場開拓をさらに妨げています。

技術革新のためには、CRCに関与する特定の神経経路に対処する標的治療薬の開発に焦点を当てるべきです。行動療法などの非薬理学的介入に関する調査も有望です。バイオテクノロジー企業と学術機関の共同研究は、画期的な発見を加速させることができます。結局のところ、CRC市場は、科学的イノベーションと戦略的パートナーシップによって大きな進歩が期待できる、ニッチではあるが有望な領域の一例であり、患者の転帰改善と経済的存続への道を開くものです。

市場力学：急速に進化する慢性難治性咳嗽市場の主要市場インサイトを解明

慢性難治性咳嗽市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性難治性咳嗽の有病率の上昇
  • 啓発と早期診断に対する政府の支援
• 市場抑制要因
  • 医薬品回収の潜在的リスク
• 市場機会
  • 効果的な医薬品開発に向けた研究開発イニシアチブの増加
  • 共同医薬品開発と医療費の改善
• 市場の課題
  • CRC治療に伴う副作用

ポーターのファイブフォース：慢性難治性咳嗽市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：慢性難治性咳嗽市場における外部からの影響の把握

外部マクロ環境要因は、慢性難治性咳嗽市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析慢性難治性咳嗽市場における競合情勢の把握

慢性難治性咳嗽市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス慢性難治性咳嗽市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、慢性難治性咳嗽市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨慢性難治性咳嗽市場における成功への道筋を描く

慢性難治性咳嗽市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性難治性咳嗽の普及率の上昇
    • 啓発と早期診断に対する政府の支援
  • 抑制要因
    • 医薬品回収の潜在的リスク
  • 機会
    • 効果的な医薬品開発に向けた研究開発の取り組みの強化
    • 共同医薬品開発とヘルスケア費削減
  • 課題
    • CRC治療に伴う副作用
• 市場セグメンテーション分析
  • 薬剤タイプ：神経障害に関連する慢性難治性咳嗽の革新的な治療薬としてガバペンチンを探索
  • 流通チャネル：慢性難治性咳嗽治療におけるオンライン薬局の好感度が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 慢性難治性咳嗽市場薬の種類別

• アミトリプチリン
• ガバペンチン
• プレガバリン

第7章 慢性難治性咳嗽市場：流通チャネル別

• ドラッグストア
• 病院薬局
• オンライン薬局

第8章 南北アメリカの慢性難治性咳嗽市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の慢性難治性咳嗽市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの慢性難治性咳嗽市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 新規呼吸器治療薬への投資急増：ノシオン・セラピューティクスのタプルカニウム開発に注目慢性難治性咳嗽
  • Trevi TherapeuticsがHaduvioの第2a相RIVER試験を開始、難治性慢性咳嗽治療の進歩
  • GSK PLC、BELLUS Health Inc.の買収を完了慢性難治性咳嗽治療ポートフォリオを強化
• 戦略分析と提言

企業一覧

• Accord Healthcare Inc.
• Alitair Pharmaceuticals
• Amneal Pharmaceuticals Inc.
• Apotex Inc.
• AstraZeneca PLC
• Aurobindo Pharma Ltd
• Bausch Health
• Bayer AG
• Cipla Inc.
• Dr Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Ltd.
• GSK PLC
• Hikma Pharmaceuticals PLC
• Intas Pharmaceuticals Ltd.
• Mylan N.V. by Viatris Inc.
• NeRRe Therapeutics
• Novartis AG
• Pfizer Inc.
• Sienna Biotec
• Strides Pharma
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Unichem Laboratories Ltd. by Ipca Labs
• Zydus Pharmaceuticals USA Inc.

LIST OF FIGURES

• FIGURE 1. CHRONIC REFRACTORY COUGH MARKET RESEARCH PROCESS
• FIGURE 2. CHRONIC REFRACTORY COUGH MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHRONIC REFRACTORY COUGH MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHRONIC REFRACTORY COUGH MARKET DYNAMICS
• TABLE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 23. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023

The Chronic Refractory Cough Market was valued at USD 5.57 billion in 2023, expected to reach USD 5.88 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 8.32 billion by 2030.

Chronic refractory cough (CRC) is a persistent cough that does not respond to standard treatments, often impacting quality of life. The scope and definition of CRC focus on its characterization as a cough lasting longer than eight weeks that remains resistant to therapeutic interventions or underlying condition management. The necessity for effective CRC treatments arises from the substantial patient discomfort and the healthcare costs associated with untreated symptoms. Applications and end-use scope include potential treatments targeting neural pathways, cough reflex modulation, and cytokine receptor antagonism, with key stakeholders including pharmaceutical companies, research institutions, and healthcare providers.

Key growth factors in the CRC market include increasing awareness of CRC among healthcare professionals, advances in diagnostic technologies, and rising investment in research for novel therapeutic approaches. Aging populations, with a predisposition towards cough-related ailments, further influence market expansion. Latest opportunities lie in personalized medicine, where tailored treatments based on genetic and phenotypic profiling could enhance therapeutic efficacy. Investing in AI-driven diagnostic tools and telemedicine platforms also presents significant potential, enabling effective CRC management remotely.

Nonetheless, market growth is constrained by challenges such as limited understanding of CRC's pathophysiology, high R&D costs, and stringent regulatory requirements. The heterogeneity of cough triggers complicates clinical trials, often requiring large-scale, long-term studies. Limited patient access to healthcare facilities, particularly in developing countries, further impedes market reach.

For innovation, focus should be on developing targeted therapeutics that address specific neural pathways involved in CRC. Research into non-pharmacological interventions, such as behavioral therapies, also holds promise. Collaborations between biotech firms and academic institutions can accelerate breakthrough discoveries. Ultimately, the CRC market exemplifies a niche yet promising area with the potential for significant advances through scientific innovation and strategic partnerships, paving the way for improved patient outcomes and financial viability.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Refractory Cough Market

The Chronic Refractory Cough Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic refractory cough
  • Government support for awareness and early diagnosis
• Market Restraints
  • Potential risk of drug recall
• Market Opportunities
  • Increasing R&D initiatives toward effective drug development
  • Collaborative drug development and improving healthcare expenditure
• Market Challenges
  • Side effects associated CRC treatment

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Refractory Cough Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Refractory Cough Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Refractory Cough Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Refractory Cough Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Refractory Cough Market

A detailed market share analysis in the Chronic Refractory Cough Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Refractory Cough Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Refractory Cough Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Refractory Cough Market

A strategic analysis of the Chronic Refractory Cough Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Refractory Cough Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Inc., Alitair Pharmaceuticals, Amneal Pharmaceuticals Inc., Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Ltd, Bausch Health, Bayer AG, Cipla Inc., Dr Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V. by Viatris Inc., NeRRe Therapeutics, Novartis AG, Pfizer Inc., Sienna Biotec, Strides Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd. by Ipca Labs, and Zydus Pharmaceuticals USA Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Refractory Cough Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Amitriptyline, Gabapentin, and Pregabalin.
• Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacies, and Online Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic refractory cough
    • 5.1.1.2. Government support for awareness and early diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. Potential risk of drug recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing R&D initiatives toward effective drug development
    • 5.1.3.2. Collaborative drug development and improving healthcare expenditure
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated CRC treatment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
  • 5.2.2. Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Chronic Refractory Cough Market, by Drug Type

• 6.1. Introduction
• 6.2. Amitriptyline
• 6.3. Gabapentin
• 6.4. Pregabalin

7. Chronic Refractory Cough Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Drug Store
• 7.3. Hospital Pharmacies
• 7.4. Online Pharmacies

8. Americas Chronic Refractory Cough Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Chronic Refractory Cough Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Chronic Refractory Cough Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough
  • 11.3.2. Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment
  • 11.3.3. GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Accord Healthcare Inc.
• 2. Alitair Pharmaceuticals
• 3. Amneal Pharmaceuticals Inc.
• 4. Apotex Inc.
• 5. AstraZeneca PLC
• 6. Aurobindo Pharma Ltd
• 7. Bausch Health
• 8. Bayer AG
• 9. Cipla Inc.
• 10. Dr Reddy's Laboratories Ltd.
• 11. Glenmark Pharmaceuticals Ltd.
• 12. GSK PLC
• 13. Hikma Pharmaceuticals PLC
• 14. Intas Pharmaceuticals Ltd.
• 15. Mylan N.V. by Viatris Inc.
• 16. NeRRe Therapeutics
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Sienna Biotec
• 20. Strides Pharma
• 21. Sun Pharmaceutical Industries Ltd
• 22. Teva Pharmaceutical Industries Ltd.
• 23. Torrent Pharmaceuticals Ltd.
• 24. Unichem Laboratories Ltd. by Ipca Labs
• 25. Zydus Pharmaceuticals USA Inc.